The Food and Drug Administration’s final guidance, “Circumstances that Constitute Delaying, Limiting, or Refusing a Drug Inspection,” describes manufacturer actions the agency views as “delaying, denying, or limiting inspection, or refusing to permit entry or inspection.”
The final document supersedes the draft document the agency issued in 2022 which expanded the FDA’s policy on inspections of drug manufacturers to include that of device firms as well. The agency based its 2022 draft on a 2014 document specific to drug companies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?